Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in CIDP
NL-OMON49386Phase 2Active, not recruiting
- Sponsor
- UCB
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rozanolixizumab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by UCB. Primary endpoint: Long-term safety and tolerability. Started Dec 2020; status: active, not recruiting.
02
Drugs
rozanolixizumab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON49386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49386.